Medicine and Health Sciences Commons^™

Managing Toxicities Associated With Immune Checkpoint Inhibitors: Consensus Recommendations From The Society For Immunotherapy Of Cancer (Sitc) Toxicity Management Working Group., I. Puzanov, A. Diab, K. Abdallah, C. O. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. E. Lacouture, N. R. Leboeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. W. Silk, D. Skondra, M. E. Suarez-Almazor, Y. Wang, K. Wiley, H. L. Kaufman, M. S. Ernstoff, J. Anderson, K. Lehman, D. Reshef, A. Saylors, M. Turner, I. Waxman, D. Arrindell, S. Andrews, J. Ballesteros, J. Boyer, I. Cotarla, M. Dawson, T. Goswami, V. Hayreh, W. Holmes, Z. Rasheed, M. Sarkeshik, J. Schreiber, K. Shafer-Weaver, D. Chen, S. Ley-Acosta, D. Chonzi, W. Go, R. Cunha, J. L. Gulley, L. Wood, M. Davies, Adam Dicker, L. Eifler, N. Gregory, A. Ferguson, C. Ferlini, S. Frankel, C. Gochett, J. Goldberg, K. Patel, D. Wariabharaj, P. Goncalves, N. Helie, J. Y. Hsu, R. Ibrahim, C. Larocca, O. Lambotte, J. Luke, J. Mcclure, E. Michelon, M. Nakamura, B. Piperdi, J. Riemer, C. Robert, W. Sharfman, E. Sharon, R. Sherry, C. Simonson, C. Thomas, E. Trehu, J. A. Thompson, D. Tresnan, L. Zhang, P. Zheng

Department of Radiation Oncology Faculty Papers

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs' therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less frequently. The majority of irAEs …